An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vericel (NASDAQ:VCEL) will report its first-quarter 2024 financial results on May 8, 2024. The company, known for advanced therapies in sports medicine and severe burn care, will host a conference call and webcast to discuss financial results and business highlights.
Vericel (NASDAQ:VCEL) comunicherà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024. L'azienda, nota per le sue terapie avanzate in medicina sportiva e cura di gravi ustioni, organizzerà una teleconferenza e un webcast per discutere i risultati finanziari e i punti salienti dell'azienda.
Vericel (NASDAQ:VCEL) reportará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024. La compañía, conocida por sus terapias avanzadas en medicina deportiva y cuidado de quemaduras graves, hospedará una llamada de conferencia y una transmisión web para discutir los resultados financieros y los aspectos destacados del negocio.
Vericel (나스닥:VCEL)은 2024년 5월 8일에 2024년 첫 분기 재무 결과를 보고할 예정입니다. 스포츠 의학 및 심각한 화상 치료에 대한 고급 치료법으로 알려진 이 회사는 재무 결과와 사업 하이라이트를 논의하기 위해 컨퍼런스 콜과 웹캐스트를 주최할 것입니다.
Vericel (NASDAQ:VCEL) annoncera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024. L'entreprise, connue pour ses thérapies avancées en médecine sportive et les soins aux brûlures graves, organisera une conférence téléphonique et une webdiffusion pour discuter des résultats financiers et des points forts de l'entreprise.
Vericel (NASDAQ:VCEL) wird am 8. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen, bekannt für fortschrittliche Therapien in der Sportmedizin und bei schweren Verbrennungen, wird eine Telefonkonferenz und einen Webcast veranstalten, um die Finanzergebnisse und Geschäftshighlights zu besprechen.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until May 8, 2025.
About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
